Trump announces trade deal with EU following months of negotiations
Scott Bertram, a director at Becton Dickinson & Co. (NYSE:BDX), recently sold 700 shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. The shares were sold at an average price of $227.99 each, amounting to a total transaction value of $159,593. Following this sale, Bertram retains ownership of 36,033 shares in the medical technology company. The transaction was executed under direct ownership, as noted in the filing.
In other recent news, BD (Becton, Dickinson and Company), a global medical technology firm, has announced plans to separate its Biosciences and Diagnostic Solutions business. The decision aims to enhance strategic focus and growth-oriented investments for both entities, potentially unlocking significant value for stakeholders. This comes after a comprehensive business portfolio evaluation initiated by BD in early 2024.
In another development, activist investor Starboard Value has reportedly acquired a stake in BD. While the exact size of the investment remains undisclosed, it is known that Starboard is advocating for the sale of BD’s life sciences division.
Moreover, during BD’s 2025 Annual Meeting, shareholders approved all Board of Directors’ nominees to serve one-year terms and ratified the appointment of Ernst & Young as the independent registered public accounting firm for fiscal 2025.
In addition, BD has authorized the repurchase of up to 10 million shares of common stock and declared a quarterly dividend of $1.04 per common share.
Lastly, Piper Sandler’s analysts have increased the price target for BD shares to $280 from $275, maintaining an Overweight rating. They suggest that a potential spin-off of the Life Sciences division could provide multiple benefits to shareholders. These are some of the recent developments involving BD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.